First Flight Venture Center
First Flight Venture Center is an incubator and venture capital firm located in Durham, North Carolina, established in 1991. It specializes in supporting early-stage and start-up companies, particularly in the technology and biotechnology sectors. The firm primarily invests in companies that are based in or relocating to North Carolina, with a specific emphasis on those in the Research Triangle Park area. First Flight typically invests between $25,000 and $500,000 in its portfolio companies. In addition to financial support, the firm provides office and laboratory space with flexible leases, shared business services, technology support, assistance in securing financing, and management guidance to help foster the growth of its ventures.
AthemBio is a biotechnology company focused on addressing significant challenges in biologics manufacturing through innovative technologies. The company specializes in developing advanced medical devices and bioprocessing systems designed to isolate and purify therapeutic antibodies. These solutions aim to enhance the treatment of COVID-19 and other infectious diseases, ultimately contributing to the fight against pandemics and emerging pathogens. AthemBio's commitment to creating effective bioprocessing solutions positions it as a key player in the healthcare sector.
Regennova is a biotechnology company dedicated to developing innovative therapies for inflammatory diseases and neurological disorders. The company's focus includes conditions such as cerebral stroke, traumatic brain injury, and Alzheimer's disease, as well as addressing challenges related to sepsis and septic shock, particularly in the context of multi-drug resistant bacteria. Through its research and development efforts, Regennova aims to provide effective treatments for conditions associated with tau-mediated diseases, thereby improving patient outcomes in these critical areas of healthcare.
Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.
Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.
Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
QUANTiSCOPE improves drug discovery by providing automated image analysis tools that are simple to integrate into research processes.
AVECRIS platform extends the capabilities of mRNA / RNA approaches. AVECRIS provides the following services: cell-type specific gene expression / Protein expression that is stable and long-lasting / Non-integrating, unlikely to elicit innate immunity / Redosable and titratable / Unprecedented ability to deliver mitochondrial gene therapy / A DNA-based backbone construct that is universal, unmodified, and has a modular coding region that allows for rapid and infinite application programming / Manufacturing that is quick, dependable, highly scalable, and low-cost.
Qatch Technologies is focused on creating innovative tools to assess the injectability and manufacturability of biopharmaceutical products. The company has developed a proprietary pre-screening technology that integrates microfluidics and acoustics, allowing for the precise measurement of viscosity using minimal liquid volumes. This advanced technology enables biopharmaceutical researchers to identify suitable injectable formulations at early stages of development, thereby streamlining the process of selecting optimal molecules for further study. By addressing potential manufacturing challenges related to viscosity, Qatch Technologies aims to enhance the efficiency and effectiveness of drug development in the biopharmaceutical sector.
Jurata Thin Film specializes in innovative storage technology for vaccines and biologics, aimed at enhancing their manufacturing, distribution, and delivery processes. The company has developed a unique thermostable film matrix that stabilizes biological materials, including bacterial-based vaccines and antibody-based therapeutics, allowing them to retain therapeutic efficacy even under extreme temperature conditions. This technology facilitates the long-term storage of vaccines and biologics at room temperature or higher, significantly simplifying logistics and accessibility. Additionally, the therapeutic cargo stored within this film can be rehydrated to recover the payload in an aqueous solution, offering versatile delivery options for healthcare providers.
PrecNA is a manufacturer of customised lipid nanoparticle formulation equipment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.